FDA溶出度方法库2730条
药品名称
剂型
USP溶出方法
转速（转/min）
溶出介质
容积
荐采样时间
更新时间
Ciprofloxacin
Oral Suspension
II (Paddle)
100
0.05 M Acetate Buffer with 0.025% Brij35 (polyoxyethylene lauryl ether), pH 4.5
900
10, 20, 30 and 45
03/25/2010
Ciprofloxacin
Injectable Suspension [Otic]
IV (Flow through cell-closed loop) / 22 mm
50 mM Acetate Buffer, pH 4.5 @37°C ± 0.5 [use glass beads; sample volume: 100 μl]
480
5, 10, 15, 20, 30, 45, 60 and 75
03/17/2016
Ciprofloxacin HCl
Tablet (Extended Release)
I (Basket)
100
0.1 N HCl
900
1, 2, 4, and 7 hours or until at least 80% released
01/14/2008
Ciprofloxacin HCl
Tablet
Refer to USP
09/02/2010
Ciprofloxacin HCl/Hydrocortisone
Otic Suspension
Develop a method to characterize in vitro release
09/01/2011
Ciprofloxacin/Ciprofloxacin HCl (AB)
Tablet (Extended Release)
II (Paddle)
50
0.1 N HCl
900
15, 30, 60, and 120
01/14/2008
Ciprofloxacin/Dexamethasone
Otic Suspension
Develop a method to characterize in vitro release
03/17/2016
Citalopram HBr
Tablet
Refer to FDA's Dissolution Guidance, 2018
07/02/2020
Citalopram Hydrobromide
Capsule
II (Paddle)
50
0.1 N HCl
900
10, 20, 30 and 45
10/06/2008
Clarithromycin
Tablet (Extended Release)
Refer to USP
10/06/2008
Clarithromycin
Suspension
II (Paddle)
50
0.05 M Phosphate Buffer, pH 6.8
900
10, 20, 30, 45 and 60
01/23/2004
Clarithromycin
Tablet
Refer to USP
07/25/2007
Clindamycin HCl
Capsule
Refer to FDA's Dissolution Guidance, 2018
07/02/2020
Clobazam
Film
V (Paddle over Disk), with 56 mm, 40 mesh stainless steel disk.
75
0.1 N HCl
900
2, 5, 10, 15, 20 and 30
04/22/2021
Clobazam
Tablet
II (Paddle)
75
0.1 N HCl (degassed)
900
5, 10, 20, 30, 45 and 60
07/31/2013
Clobazam
Oral Suspension
II (Paddle)
75
0.1 N HCl (degassed)
900
5, 10, 15, 20, 25 and 30
07/31/2013
Clomiphene Citrate
Tablet
Refer to USP
08/15/2013
Clomipramine HCl
Capsule
Refer to FDA's Dissolution Guidance, 2018
07/02/2020
Clonazepam
Tablet
Refer to FDA's Dissolution Guidance, 2018
07/02/2020
Clonazepam
Tablet (Orally Disintegrating)
II (Paddle)
50
Water
900
5, 10, 15, 30, and 45
07/25/2007